Skip to content
Medical Health Aged Care

Scanfil Strengthens its Customer Portfolio in Medtech & Life Science by Signing Agreement with Liquid Instruments

Scanfil 2 mins read
MELBOURNE, Australia--BUSINESS WIRE--

Scanfil and Liquid Instruments have signed a manufacturing outsourcing agreement for Scanfil’s Melbourne plant in Australia. This agreement supports Liquid Instruments’ strategy to onshore production of its flagship Moku platform, strengthening domestic supply chains and bringing manufacturing closer to its research and development hub.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625717512/en/

This agreement supports Liquid Instruments’ strategy to onshore production of its flagship Moku platform, strengthening domestic supply chains and bringing manufacturing closer to its research and development hub. Photo by Scanfil.

This agreement supports Liquid Instruments’ strategy to onshore production of its flagship Moku platform, strengthening domestic supply chains and bringing manufacturing closer to its research and development hub. Photo by Scanfil.

“We’re continuing to expand our manufacturing footprint in Australia,” says Daniel Shaddock, CEO of Liquid Instruments. “Onshoring production through this partnership allows us to scale more efficiently, while deepening our investment in Australia’s technology ecosystem. Scanfil’s expertise and strong local presence make them the ideal partner for this next phase of growth.”

The collaboration will leverage Scanfil's and its subsidiary, SRXGlobal's, expertise in Medtech & Life Science. Liquid Instruments will benefit from supply chain management, scalable manufacturing, global delivery capabilities, and aftermarket services — all in Victoria, Australia.

"Liquid Instruments has developed a unique product with an interesting and complex technology that is a perfect fit for the services provided by SRXGlobal in Australia. We at Scanfil and SRXGlobal are thrilled and excited that Liquid Instruments has chosen SRXGlobal as their preferred manufacturing partner for the exciting journey ahead, and we look forward to a strong and successful partnership", states Christian Kesten, VP of Scanfil APAC.

Scanfil in brief

Scanfil plc is Europe’s largest listed provider of electronics manufacturing services (EMS), whose turnover in 2024 amounted to EUR 780 million. The company serves global sector leaders in the customer segments of Industrial, Energy & Cleantech, and Medtech & Life Science. The company’s services include design services, prototype manufacture, design for manufacturability (DFM) services, test development, supply chain and logistics services, circuit board assembly, manufacture of subsystems and components, and complex systems integration services. Scanfil’s objective is to grow customer value by improving their competitiveness and by being their primary supply chain partner and long-term manufacturing partner internationally. Scanfil’s longest-standing customer account has continued for more than 40 years. The company has global supply capabilities and eleven production facilities across four continents. www.scanfil.com


Contact details:

Further information:
Christian Kesten
Vice President, APAC region
tel. +86 512 67168867 6101
[email protected]

Pasi Hiedanpää
Director, Investor Relations and Communications
tel. +358 50 378 2228
[email protected]

Media

More from this category

  • Medical Health Aged Care, Science
  • 22/01/2026
  • 10:00
Monash University

Patients co-design world-first clinical trial to determine if invasive heart surgery monitoring helps or harms patients

Australians undergoing open-heart surgery could soon benefit from safer, simpler care and get home earlier thanks to the results of a world-first clinical trial…

  • Contains:
  • Medical Health Aged Care, Science
  • 22/01/2026
  • 08:00
La Trobe University

Drinking less could prevent thousands of cancer deaths, study shows

Reducing annual alcohol consumption in Australia by one litre a person could significantly lower deaths from several major cancers, particularly among older Australians, a new study led by La Trobe University has found. Using more than 70 years of national mortality, alcohol and tobacco consumption, and health-expenditure data, researchers examined how long-term population level alcohol consumption in Australia is associated with mortality from four alcohol-related cancers. Published in the British Journal of Cancer, the study said that long-term alcohol exposure was a causal factor in: Some 45 per cent of male upper aerodigestive tract (UADT) cancer deaths About 21 per…

  • Medical Health Aged Care
  • 22/01/2026
  • 08:00
Monash University

New clinical trial to compare the effectiveness of IV treatments for severe asthma in children

A clinical trial to determine the best intravenous (IV) treatments for children with severe asthma will go ahead thanks to an almost $5 million Medical Research Future Fund grant. The clinical trial – spearheaded by Professor Simon Craig, Adjunct Clinical Professor in the School of Clinical Sciences at Monash Health and paediatric emergency medicine physician at Monash Medical Centre – will provide clinicians with clear evidence to make more informed decisions, provide faster and more effective treatment, reduce unnecessary variation between hospitals, and ultimately improve outcomes for children with severe asthma. “Asthma is one of the most common reasons children…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.